Growth Metrics

Aurinia Pharmaceuticals (AUPH) Gains from Investment Securities (2020 - 2025)

Aurinia Pharmaceuticals' Gains from Investment Securities history spans 6 years, with the latest figure at $7.7 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 306.8% year-over-year to $7.7 million; the TTM value through Dec 2025 reached $16.9 million, up 119.86%, while the annual FY2025 figure was $2.8 million, 28.94% up from the prior year.
  • Gains from Investment Securities reached $7.7 million in Q4 2025 per AUPH's latest filing, up from -$5.9 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $90.7 million in Q4 2023 to a low of -$5.9 million in Q3 2025.
  • Average Gains from Investment Securities over 5 years is $7.7 million, with a median of $3.0 million recorded in 2022.
  • Peak YoY movement for Gains from Investment Securities: skyrocketed 32229.41% in 2024, then plummeted 5329.36% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at $5.8 million in 2021, then plummeted by 86.53% to $782000.0 in 2022, then skyrocketed by 11493.09% to $90.7 million in 2023, then plummeted by 104.09% to -$3.7 million in 2024, then soared by 306.8% to $7.7 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Gains from Investment Securities are $7.7 million (Q4 2025), -$5.9 million (Q3 2025), and $6.2 million (Q2 2025).